期刊文献+

尼妥珠单抗临床试验研究进展 被引量:6

Rmemch Progress of Clinical Triak of Nimotumab
下载PDF
导出
摘要 尼妥珠单抗(Nimotuzumab,h-R3)是我国第一个表皮生长因子受体为靶点的人源化单克隆抗体药物.能够竞争性结合表皮生长因子受体.抑制肿瘤细胞增殖、促进细胞凋亡.抑制肿瘤血管生成。临床试验显示,其对于多种上皮源肿瘤具有良好的疗效,疾病控制率高.不良反应轻微.患者生存获益显著。 Nimotuzumab (h-R3) is the first approved humanized monoclonal antibody targeted the epidermal growth factor receptor in China. It competitively binds epidermal growth factor receptor, promotes apoptosis, and inhibits tumor cell proliferation and tumor angiogenesis. Clinical trials show that nimotuzumab could effectively treat a variety of epithelial tumors with high rate of disease control and mild adverse reactions. Significant survival benefit could be observed in clinical trials.
出处 《药品评价》 CAS 2011年第22期16-21,共6页 Drug Evaluation
关键词 尼妥珠单抗:表皮生长因子受体(EGFR) 单克隆抗体 临床试验 Nimotuzumab Epidermal growth factor receptor (EGFR) Monoclonal antibody Clinical trials
  • 相关文献

参考文献16

  • 1Mateo C,Moreno E,Amour K,et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor:, recovery of antagonistic activity [J]. Immunotechnology. 1997,3:71-81.
  • 2Cmmbet T, Torfes L,Neninger E,et al.Phannacological evaluation ofhtrnanized anti-epidermal growth factor , monoclonat antibody h-R3, in patients with advanced epithelial-derived cancer[J] .J.Immunother,2003,26:139-48.
  • 3Cmmbet T, Osofio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in file treatment oflecally advanced head and neck cance~ patients [J]. J. Clin. Oncol. 2004; 22: 1646-54.
  • 4Ramakrishnan M,Eswaraiah A,Crombet T, et al.Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin[J]. mAbs,2009,1:41-8.
  • 5Rodrlguez M,Rivero T, Bahi R,et al.Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Bio. Ther,2010,9(5):343-49.
  • 6Bode U,Buchen S,Warmuth-Metz M,et al.Final report of a phase 11 trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents [J].Hematology Meeting Reports. 2007; 1(6): 65-66.
  • 7汪洋,潘力,毛颖,张荣,庄冬晓,高晶,陈淑,戴嘉中,盛晓芳.尼妥珠单抗联合放疗加同期替莫唑胺治疗高分级胶质瘤的初步研究[J].中国癌症杂志,2009,19(11):856-860. 被引量:29
  • 8黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 9Bebb G,Smith C, Rorke S,et al.Phase 1 clinical trial of the anti-EGFR monoclonal antibody nimotuztunab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage lib, IIl or IV non-small cell lung cancer unsuitable for radical therapy [J].Cancer Ch emother, Pharmacol,2011,67:837-45.
  • 10Choi H,Sohn J, Lee C,et al.A phase I study of nimotuzumab in combination with radiotherapy in stages IIB IV non-small cell lung cancer unsuitable for radical therapy: Korean results [J].Lung Cancer,2011,71:55-59.

二级参考文献46

  • 1王树森,管忠震,向燕群,姜文奇,林桐榆,张力.表皮生长因子受体酪氨酸激酶抑制剂Gefitinib对鼻咽癌荷瘤裸鼠移植瘤生长作用的实验研究[J].癌症,2004,23(z1):1365-1369. 被引量:9
  • 2黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 3Naravan NA, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results [ J ]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 892- 897.
  • 4Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy [J]. Cancer, 2002, 94(5): 1593-1611.
  • 5Chakravarti A, Berkey B, Robins HI, et al. An update of phase I / II study of gefitinib with radiotherapy in newly diagnosed glioblastoma[J].J Clin Oncol, 2006, 24(18suppl): 1527.
  • 6Brown PD, Krishnan S, Sarkaria JN, et al. Phase I /II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma muhiforme: North Central Cancer Treatment Group Study N0177 [ J ] . J Clin Oneol, 2008,26(34): 5603-5609.
  • 7Tania CR, Javier F, Mauricio C, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor(EGFR) antibody h-R3: Report from a phase I /II trial [ J ] . Cancer Biol Ther, 2006, 5(4): 375-379.
  • 8Stephanie E, Combs MN, Lutz E, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of- care postoperative radiation alone in patients with WHO grade Ⅲ astrocytic tumors [ J ] . Radiother Oncol, 2008, 88(2): 177-182.
  • 9Stupp R, Waren P. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].N Engl J Med, 2005, 352(10): 987-996.
  • 10Herrlinger U, Reiger J, Koch D, et al. Phase Ⅱ trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 [ J ] . J Clin Oncol, 2008, 24(27): 4412-4417.

共引文献117

同被引文献78

  • 1彭娟,丁童,郑利民,邵建永.肿瘤相关巨噬细胞对鼻咽癌进展和预后的影响[J].癌症,2006,25(11):1340-1345. 被引量:17
  • 2黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 3吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 4周际昌.实用肿瘤内科学[M].北京:人民卫生出版社.2006:47
  • 5杨国梁,郑树.消化系统恶性肿瘤诊疗学[M].北京:科学出版社,2008:147.
  • 6万钧,高献书.食管癌单纯外照射结束时疗效(近期疗效)的评价及标准[M].北京:原子能出版社,2000:46-49.
  • 7Mehra R,Cohen RB,Burtness BA.The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck[J].Clin Adv Hematol Oncol,2008,6(10):742-750.
  • 8Mayte,Lima Perez.5th Nimotuzumab Global Scientific Meeting[C].Havana,2009.
  • 9Sibata CH,Colussi VC,Kinsella TJ.Photodynamic therapy in oncology[J].Expert Opin Pharmacother,2010,2(6):917-927.
  • 10Ahmed AA,Wang X,Lu Z,et al.Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel[J].Cancer Res,2011,71(17):5806-5817.

引证文献6

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部